Fluvoxamine (DU-23000) is an antidepressant that functions as a selective serotonin reuptake inhibitor.

Fluvoxamine (DU-23000) effectively blocks 5-HT (serotonin) uptake in blood platelets and brain synaptosomes, differing from desmethylimipramine and imipramine by not inducing stimulatory effects in rats given reserpine-like compounds. It counters the reserpine-induced reduction in pentamethylenetetrazole seizure threshold via its action on 5-HT uptake. Though it shows promise in alleviating symptoms of combat-related PTSD, the absence of a placebo group and high dropout rate in the study call for more controlled research. Additionally, fluvoxamine's efficacy in reducing ethanol intake varies with its availability, demonstrating reduced potency when food is present alongside ethanol, an insight critical for understanding its therapeutic potential in substance use contexts.